Impact of 13Valent Vaccine for Prevention of Pneumococcal Diseases in Children and Adults at Risk: Possible Scenarios in Campania Region

(E-pub Ahead of Print)

Author(s): Alessandro Sanduzzi, Angelo Canora*, Patrizia Belfiore, Marialuisa Bocchino, Renato Liguori, Giorgio Liguori.

Journal Name: Infectious Disorders - Drug Targets

Submit Manuscript
Submit Proposal

Abstract:

Background: Pneumonias are the most frequent infectious diseases, characterized by a high prevalence especially among children and adults at risk. The socio-economic impact caused by Streptococcus pneumoniae is evaluated in terms of morbidity, death rate and hospitalizations. Objective: The aim of the study was to demonstrate the potential economic advantages by implementation of an active anti-pneumococcal 13-valent vaccine strategy in Campania region (Southern Italy) in two different categories of subjects, children (aged 0-12), and adults (aged 50- 79) at risk (hypertension, nephropathies, COPD and heart diseases) Methods: Vaccination costs were compared with costs necessary to treat avoidable diseases in the presence and absence of a vaccination program. Results: Offering anti-pneumococcal 13-valent vaccine to the paediatric population was quantified as saving one million euros for Italian national health service in two years. In addition, offering anti-pneumococcal vaccine to adults at risk would generate a return of around 29 million euros. Conclusion: In both cases, offering anti-pneumococcal 13-valent vaccine was proven to be a helpful political health strategy, not only in consideration of a reduction of cases but also in view of the favourable economic impacts.

Keywords: Budget Impact Analysis , 13 valent vaccine, Pneumococcal diseases

Rights & PermissionsPrintExport Cite as


Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1871526518666180820161630
Price: $95

Article Metrics

PDF: 1